A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of I therapy: a speculative paper

Nuclear Medicine Communications

Volumn 27, Issue 5, 2006, Pages 439-446

  Traino, Antonio C ^a   Di Martino, Fabio ^a   Grosso, Mariano ^b   Monzani, Fabio ^b   Dardano, Angela ^b   Caraccio, Nadia ^c   Mariani, Giuliano ^c   Lazzeri, Mauro ^c  

^a Sezione di Fisica Medica   (United States)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Dosimetry; Graves' disease; Thyroid; Thyroid volume

Indexed keywords

IODINE 131; THYROID HORMONE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CALCULATION; DOSIMETRY; DRUG ABSORPTION; DRUG UPTAKE; GRAVES DISEASE; MATHEMATICAL MODEL; NONPARAMETRIC TEST; OUTCOME ASSESSMENT; PREDICTION; RADIATION ABSORPTION; RADIATION DOSE; RANK SUM TEST; THYROID HORMONE BLOOD LEVEL; THYROID HORMONE SYNTHESIS; THYROID MASS; TREATMENT OUTCOME; ADULT; AGED; BIOLOGICAL MODEL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER SIMULATION; EVALUATION; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PILOT STUDY; PROGNOSIS; RADIATION DOSE FRACTIONATION; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; COMPUTER SIMULATION; DOSE FRACTIONATION; FEASIBILITY STUDIES; FEMALE; GRAVES DISEASE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 33745937322     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200605000-00005     Document Type: Article

References (17)

1. Catargi B, Leprat F, Guyot M, Valli M, Ducassou D, Tabarin A. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome. Eur J Endocrinol 1999; 141:117-121.
2. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves' hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid 1997; 7:247-251.
3. Jönsson H, Mattsson S. Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism. Radiat Prot Dosim 2004; 108:107-114.
4. Jönsson H, Mattsson S. Current methods for absorbed dose planning for radioiodine treatment of hyperthyroidism in Sweden. Phys Med 2004; 20:99-103.
5. Jarlov AE, Hegedüs L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxford) 1995; 43:325-329.
6. Reinhardt MJ, Brink I, Joe AY, von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med 2002; 29:1118-1124.
7. Bajnok L, Mezosi E, Nagy E, Szabo J, Sztojka I, Varga J, et al. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary? Thyroid 1999; 9:865-869.
8. Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Eur J Nucl Med 2001; 28:1489-1495.
9. Muratami Y, Takamatsu J, Sakane S, Kuma K, Ohshawa N. Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid stimulating antibody and treatment outcome. J Clin Endocrinol Metab 1996; 81:3257-3260.
10. Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998; 83:40-46.
11. Haase A, Bahre M, Lauer I, Meller B, Richter E. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose. Exp Clin Endocrinol Diabetes 2000; 108:133-137.
12. Gomez-Arnaiz N, Andia E, Guma A, Abos R, Soler J, Gomez JM. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism. Horm Metab Res 2003; 35:492-497.
13. 131I. Phys Med Biol 2005; 50:2181-2191.
14. Di Martino F, Traino AC, Brill AB, Stabin MG, Lazzeri M. A theoretical model for prescription of the patient-specific therapeutic activity for radioiodine therapy of Graves' disease. Phys Med Biol 2002; 47:1493-1499.
15. Traino AC, Di Martino F, Lazzeri M. A dosimetric approach to patient specific radioiodine treatment of Graves' disease with incorporation of treatment induced changes in thyroid mass. Med Phys 2004; 31:2121-2127.
16. Stabin MG. Internal radiation dosimetry. In: Hankin RE, et al. (editors): Nuclear Medicine, Volume I. St. Louis: Mosby; 1996, pp. 316-333.
17. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131-iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995; 25:186-193.